Johannesburg, South Africa, and Washington — Results of an advanced clinical trial of an antiretroviral-based microbicide candidate are being announced at the International AIDS Conference in Vienna, Austria. The CAPRISA 004 trial, which tested the safety and effectiveness of 1 percent tenofovir gel among nearly 900 women at two sites in South Africa, found that using the gel before and after sex provided moderate protection against sexually transmitted HIV.
“This is an important day,” said Yasmin Halima, director of the Global Campaign for Microbicides. “We now have evidence that a vaginal gel can help prevent HIV. This is good news for women, good news for the field, and a good day for science.”
“Today’s news energizes the field,” Halima said. “We hope it urges others to support the expansion of programs for developing topical HIV-prevention products. Globally, millions remain at risk of HIV, and yet to date, there are few options to prevent infection, especially for women.”
“While we pause to mark this important milestone, we can’t afford to idle,” she said. “We must keep up the momentum. We won’t rest until there are tools for HIV prevention in women’s hands. With the support of donors, governments, scientists, and communities working together, the HIV-prevention field can accelerate efforts to halt the pandemic, focusing on the world’s most vulnerable people. Today’s news brings us one step closer to that brighter future.”
More information about the CAPRISA 004 trial is available on the Global Campaign for Microbicides website.
About the trial
The CAPRISA 004 trial tested a microbicide gel that contained a drug called tenofovir. Tenofovir is an antiretroviral (ARV) drug that is used as an oral treatment for HIV in many countries and is licensed for use as HIV treatment in South Africa. CAPRISA 004 is the first trial to evaluate an ARV-based candidate microbicide gel for the prevention of sexually transmitted HIV infection among women. The trial commenced enrolment in May 2007 and completed follow-up in December 2009. The results of the trial will be released today, July 19, 2010, at the International AIDS Conference in Vienna, Austria.
The CAPRISA 004 trial was conducted at two CAPRISA (Centre for the AIDS Programme of Research in South Africa) clinical research sites in the KwaZulu-Natal Province of South Africa: in an urban area of eThekwini (Durban) and a rural area of Vulindlela (Pietermaritzburg).
The CAPRISA 004 trial enrolled 889 South African women who were 18 to 40 years of age, HIV-negative, sexually active, and at high risk of becoming infected with HIV. Women in the trial were asked to vaginally insert a first dose of tenofovir gel no more than 12 hours before having sex and to insert a second dose no more than 12 hours after having sex. No more than 2 doses of gel were used in a 24-hour period, even if the women had sex more than once.
CAPRISA 004 was a relatively small trial (called a Phase 2b trial), as it was designed to explore whether tenofovir gel was a promising microbicide candidate. It was not designed to provide sufficient evidence to license a new drug (which would generally require a definitive Phase 3 trial). The CAPRISA 004 trial measured whether tenofovir gel reduced the risk of HIV infection among women provided with the tenofovir gel compared to women provided with a placebo gel. All participants received regular HIV risk-reduction counseling, condoms, and treatment of symptomatic sexually transmitted infections, if required.
The CAPRISA 004 trial also measured whether tenofovir gel was safe to use regularly over a longer period of time than had previously been assessed in clinical safety studies. Women in the trial typically used the gel for 12 to 18 months. The trial systematically collected information on all health complications, genital events, and systemic toxicity (if the drug reached the blood stream). The CAPRISA 004 trial also assessed if women who seroconverted during the trial developed resistance to tenofovir and the effect that using tenofovir gel for HIV prevention had on the HIV viral load after seroconversion.
The trial was conducted by a consortium that included the Centre for the AIDS Programme of Research in South Africa (CAPRISA) at the University of KwaZulu-Natal in Durban; Family Health International, North Carolina, USA; and CONRAD, Virginia, USA. It was funded by the United States Agency for International Development (USAID) and TIA, a biotechnology agency of the South African government’s Department of Science and Technology. In addition, Gilead Sciences provided tenofovir for the manufacture of the gel used in the study.
Microbicides are being developed as products that could be topically applied by a receptive sex partner to reduce risk of becoming HIV infected during sex. Microbicide candidates are being formulated as vaginal gels, suppositories, foaming tablets, or slow-releasing vaginal rings.
More information about microbicides is available on the Global Campaign for Microbicides website.
About the Global Campaign for Microbicides
The Global Campaign for Microbicides is a civil society organization working to ensure the ethical and accelerated development of, and widespread access to, new and existing HIV-prevention options—especially for women. The campaign’s secretariat is housed at PATH. For more information about the campaign, visit the Global Campaign for Microbicides website or email [email protected].
Contact: Melissa May, communications director, Global Campaign for Microbicides, 202.412.9362, +43(0) 688 919 8109, [email protected]